Slater Technology Fund — 2025 Investments
1 investments dated 2025 · listed companies and verified rows first · show all
MindImmune develops therapeutics targeting the immune drivers of neurodegenerative diseases such as Alzheimer's, focusing on immune cells that respond to amyloid plaques before they enter the brain.
BiotechHealthtechKingston, US
Robert B. Nelson(Executive Officer, Director)Frank S. Menniti(Executive Officer, Director)inStevin Zorn(Executive Officer, Director)inIsaac Stoner(CEO)in
BoardRichard G. Horan(Director)Reetika Bhardwaj(Director)in
Co-investorsDolby Family VenturesPfizer Venture InvestmentsARCH Venture PartnersPfizer Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.

